Developing Innovative Peptides

Investor Presentation

30 June 2017
Disclaimer

This presentation contains certain statements and may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by ImmuPharma PLC ("the Company") in respect of itself and its subsidiaries ("ImmuPharma"). These factors include, but are not limited to: (i) ImmuPharma's and/or ImmuPharma's partners' ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialisation; (ii) ImmuPharma's and/or ImmuPharma's partners' ability to obtain required governmental approvals, including product and patent approvals, the impact of pharmaceutical industry regulation, the difficulty of predicting FDA and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries; (iii) the acceptance and demand for new pharmaceutical products and ImmuPharma's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) ImmuPharma's and/or ImmuPharma's partners' ability to develop and commercialise products before its competitors and the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of products, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development. In addition, significant fluctuations in financial results may occur as a result of the timing of milestone payments and the timing of costs and expenses related to ImmuPharma's research and development program. Without limiting the generality of the foregoing, no assurance is given as to when ImmuPharma's products will be launched or whether that launch will be commercially successful, and words such as "may," "will," "to," "expect," "plan," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties. No reliance may be placed, for any purposes whatsoever, on the information contained in this presentation or on its completeness and this presentation should not be considered a recommendation by the Company or any of their respective affiliates in relation to any purchase of or subscription for securities of the Company.

Save in the case of fraud, no liability is accepted for any errors, omissions or inaccuracies in such information or opinions. This presentation is being made only in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “FPO”), (ii) persons in the business of disseminating information within the meaning of Article 47 of the FPO, (iii) high net-worth companies, unincorporated associations and other bodies within the meaning of Article 49 of the FPO and (iv) persons to whom it is otherwise lawful to make the presentation. The investment or investment activity to which this presentation relates is available only to such persons and will be engaged in only with such persons. Persons who fall outside categories (i) - (iii) above must check that they fall within category (iv). If they do not, they may not attend this presentation. Any person who does not fall within categories (i) - (iv) above may not rely on or act upon the matters communicated at this presentation. Any person falling outside categories (i) - (iv) who has received any document forming part of this presentation must return it immediately. Neither this presentation nor any copy of it may be (i) taken or transmitted into the United States of America, (ii) distributed, directly or indirectly, in the United States of America or to any US person (within the meaning of regulations made under the Securities Act 1933, as amended), (iii) taken or transmitted into or distributed in Canada, Australia, the Republic of Ireland or the Republic of South Africa or to any resident thereof, or (iv) taken or transmitted into or distributed in Japan or to any resident thereof. Any failure to comply with these restrictions may constitute a violation of the securities laws or the laws of any such jurisdiction. The distribution of this document in other jurisdictions may be restricted by law and the persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. This presentation is being made on the basis that the recipients keep confidential any information contained herein or otherwise made available, whether orally or in writing, in connection with the Company. This presentation is confidential and must not be copied, reproduced, published, distributed, disclosed or passed to any other person at any time without the prior written consent of an agent for the Company or ImmuPharma.
Management team

Tim McCarthy  
Chairman

Dimitri F. Dimitriou  
Chief Executive Officer

Dr Robert Zimmer  
Chief Scientific Officer

Franco D’Muzio  
Non-Exec Director

Dr Stéphane Méry  
Non-Exec Director

Tracy Weimar  
VP Ops & Finance

Lisa Baderoon  
Head of Investor Relations
Today’s presentation

1. Introduction
2. Recent fundraising history
3. Pipeline summary
   - Lupuzor™
   - Nucants
   - Peptide platform
4. Update on Lupuzor™ Phase III pivotal trial
5. IR strategy
6. Summary

• Vadim Alexandre, Healthcare Analyst at Northland
  • Overview of ImmuPharma’s investment case

Q&A
Company summary

- Pharma development company listed on AIM since 2006 (LSE:IMM)
- Lead drug candidate, Lupuzor™, for the treatment of Lupus, a life threatening autoimmune disease
  - Phase III pivotal study ongoing
  - Substantial ‘blockbuster’ market potential
- P140 platform with potential to target further autoimmune diseases
- Nucants platform with two Phase I trials completed for potential use in combination cancer treatments and in age related macular degeneration (AMD) and diabetic retinopathy
- Peptide technology platform
- Longstanding collaboration with Centre National de la Recherche Scientifique (CNRS)
  - Europe’s largest research institution
- Experienced management and research team
- Low-cost business model based on outsourcing (c. 20 people)
Continued value creation

March ‘17
£4.1m Equity Placing

Oct ‘16:
£3.5m Vendor Placing & Equity Issue

Feb ‘16:
£8.4 million Placing & Subscription
Recent IR activities: Jan to June

- Over 15 RNS Releases
- Over 40 Presentations & Meetings
- Over 20 Interviews
Investor conferences

Biotech & Money - Feb -

Biotech Capital - Feb -

Master Investor Show - April -
Pipeline overview

Forigerimod
P140
Lupuzor

Autoimmune Diseases

Nucants
IPP-204106

Oncology
Ophthalmology

Peptide Platform

Metabolic Disorders

Purpose-modified peptides.
Discovery phase.
Diabetes, Nonalcoholic Steatohepatitis (NASH) and other metabolic diseases.

Family of peptides for cancer and ophthalmology.
Phase IIa completed.
Potential for Phase II studies in cancer and Age-related Macular Degeneration and/or diabetic retinopathy. Potential for other indications.

Treatment of Lupus.
Unmet opportunity.
Phase III trial ongoing.
Potential application in other autoimmune diseases.
What is Lupus?

- Lupus is an autoimmune chronic inflammatory disease, sometimes fatal, associated with disorders of the immune system
- Unmet market need, due to the lack of safe and effective treatments
- Multi-billion sales potential
- Varying patient estimates*:
  - an estimated 5 million people globally suffer from lupus
  - 1.5 million lupus sufferers in Europe/US/Japan
- Current drugs have serious side-effects and limited effectiveness
- GSK’s approval of Benlysta paves the path to market
- **ImmuPharma’s Lupuzor™ in a pivotal Phase III trial**

* source: Lupus Foundation of America ‘www.lupus.org’ (2017)
Lupuzor™ key USP’s

- Novel mechanism that modulates (*not blocks*) the immune system
- Phase IIb demonstrated a significant efficacy in the treatment of Lupus together with outstanding safety
- Lupuzor™ granted *Fast Track* status by the US FDA and approval for pivotal phase III trial under *Special Protocol Assessment*
- Attractive economics
**Lupuzor™ - mechanism of action**

**Without P140**

- APC
- MHC-peptide-TCR
- Proinflammatory Cytokines
- Proinflammatory Cytokines
- B cell
- BCR
- Antibody secreting cells
- Damaging autoantibodies

**with P140**

- No activation
- No autoantibodies

**ImmuPharma**
# Lupuzor™ phase IIb final data

<table>
<thead>
<tr>
<th></th>
<th>Lupuzor™</th>
<th>Benlysta*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Duration of treatment</strong></td>
<td>3 months N=86</td>
<td>12 months N=548</td>
</tr>
<tr>
<td><strong>Drop-out rate % (active/placebo)</strong></td>
<td>8% / 16%</td>
<td>23% / 25%</td>
</tr>
<tr>
<td><strong>% Responder active</strong></td>
<td>62%</td>
<td>43%</td>
</tr>
<tr>
<td><strong>% Responder placebo</strong></td>
<td>38%</td>
<td>33%</td>
</tr>
<tr>
<td></td>
<td>p &lt; 0.025</td>
<td>p &lt; 0.025</td>
</tr>
<tr>
<td><strong>Clinical impact</strong></td>
<td>+ 25%</td>
<td>+ 10%</td>
</tr>
</tbody>
</table>

*Based on published data: Lupuzor (Zimmer et al. 2012); Benlysta (Furie et al. 2011)  
*Phase III study*
Nucants: A new concept

• Peptide that binds with high affinity to nucleolin (nM)
• Nucleolin is highly expressed at the surface of dividing cells (cancer cells)
• Potential cancer cell targeting tool
• Nucants are cytotoxic on their own
• Nucants modulate the improper micro-vasculature:
  • Ameliorates (enhances) the tumor blood flow
  • Improves the poor vascularization in DMLA and diabetic retinopathy
Nucants: Clinical development

- Two Phase I studies completed for tolerability and safety
- Efficacy Phase II in pancreatic cancer in combination with gemcitabine next steps
- Potential to target further cancer indications in the future
Mechanism of Action of N6L (Nucant) published in ‘Cancer Research’

N6L is the lead compound of the Nucant family

The key findings:

- Nucleolin inhibition is a new anti-cancer therapeutic strategy that has been shown to dually normalise tumour vasculature and reduce its volume

- As a result, it has the potential to improve dramatically the delivery and efficacy of existing chemotherapeutic drugs, and in particular, for difficult-to-treat tumours such as Pancreatic cancer
PEPTIDE PLATFORM

Dr Robert Zimmer
UREkA: The Bordeaux Division
Why Urelix technology?

• Peptides and receptors are fundamental to the body’s function. Present in very limited quantities; important “in vivo” turnover; importance of control systems (regulation)
• Peptides are fragile and can be easily broken down or displaced

• *Urelix* can make peptides more stable
• *Urelix* and natural peptides need to be as similar as possible to undergo the same pathway and the controls
Potential clinical targets

The technology is more suited for certain peptides therefore selected diseases

a. Cancer (protein/protein interaction)
b. Diabetes Type II: 390 m sufferers
c. NASH: Non-Alcoholic Steato-Hepatitis*

* Globaldata recently valued the potential at 25 bn US$ in 2016 with a double-digit increase per year
Phase III Trial Update

Tim McCarthy
Lupuzor™ phase III trial

- Phase III ongoing – 28 investigator sites
  - 11 centres in the US
  - 16 centres in Europe
  - 1 centre in Mauritius
  - Simbec-Orion (CRO) experts in Lupus trials
- Protocol agreed with the FDA
  - One year dosing
  - Protocol similar to that of Phase IIb
  - n = 200 patients/study
  - Double-blind, Randomised, Placebo controlled; once a month (dose 0.2mg)
- Top line data expected during Q1 2018

Find more information on: www.ClinicalTrials.gov/lupuzor
Lupuzor™ phase III trial - study highlights

- 200 patients successfully recruited and randomised (dosed)
  - 293 patients initially screened illustrating the demand from physicians for a new safe and effective treatment for Lupus

- Study status as at the end of June 2017
  - All 200 patients have passed the 3 months stage
  - Over 90% of patients (184) have passed 6 months
  - 81 patients (40%) have passed the 9 months stage
  - Over 23% of patients (46) have passed the full 12 months of the study

- Continued robust safety record which remains consistent with Lupuzor™’s product profile as shown in its previous Phase IIb study

Find more information on: www.ClinicalTrials.gov/lupuzor
Lupuzor™ phase III key milestones

2015
- US sites open and recruitment commences
- Investigator Meeting

2016
- First dosing of US patients
- European sites open and recruitment commences
- First European patients dosed
- Additional site in Mauritius
- Completion of recruitment of 200 patients

2017
- Further progress updates on trial

2018
- Last patient completes treatment
- Top-line Phase III results
**Investment rationale**

- Lupuzor™ is a potential blockbuster asset owned 100% by ImmuPharma
- Pivotal phase III trial on track
- Awarded Special Protocol Assessment and Fast Track designation by FDA
- Competitive efficacy & safety profile
- Collaboration partnership with CNRS
- P140 platform provides potential to expand into other autoimmune diseases
- Earlier stage development pipeline from pre-clinical through to Phase II
- Value enhancing news-flow anticipated over medium term
- Intensive IR strategy ongoing
• Vadim Alexandre, Healthcare Analyst at Northland
  • Background
  • Investment case
  • Valuation
ImmuPharma plc
50 Broadway
Westminster
London SW1H 0RG
U.K.

Tel: +44 20 7152 4080
www.immupharma.com

Contact
tim.mcarthy@immupharma.com
dimitri.dimitrou@immupharma.com
lisa.baderoon@immupharma.com

Twitter : @immupharma

UK Advisers

Nominated Advisor & Broker
Northland Capital Partners Ltd

Public Relations & Investor Relations
lisa.baderoon@immupharma.com
Capital Access Group

Auditors
Nexia Smith & Williamson

Solicitors
Bircham Dyson Bell